Larimar Therapeutics, Inc. financial data

Symbol
LRMR on Nasdaq
Industry
Pharmaceutical Preparations
Location
Three Bala Plaza East. Suite 506, Bala Cynwyd, PA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ZAFGEN, INC. (to 5/19/2020), ZAFGEN INC (to 11/3/2008)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.3K % -1.61%
Debt-to-equity 11.1 % -10.8%
Return On Equity -37.8 % -26.3%
Return On Assets -34.1 % -27.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.8M shares +47.4%
Common Stock, Shares, Outstanding 63.8M shares +47.5%
Entity Public Float 20.6M USD -78.2%
Common Stock, Value, Issued 64K USD +48.8%
Weighted Average Number of Shares Outstanding, Basic 63.8M shares +45.3%
Weighted Average Number of Shares Outstanding, Diluted 63.8M shares +45.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 49.9M USD +115%
General and Administrative Expense 16M USD +23.2%
Operating Income (Loss) -65.8M USD -81.8%
Nonoperating Income (Expense) 7.5M USD +110%
Net Income (Loss) Attributable to Parent -58.3M USD -78.7%
Earnings Per Share, Basic -1.11 USD/shares -48%
Earnings Per Share, Diluted -1.11 USD/shares -48%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.3M USD -65.7%
Cash, Cash Equivalents, and Short-term Investments 226M USD +117%
Assets, Current 231M USD +117%
Property, Plant and Equipment, Net 844K USD +24.7%
Operating Lease, Right-of-Use Asset 3.21M USD +24.6%
Other Assets, Noncurrent 636K USD -1.24%
Assets 237M USD +112%
Accounts Payable, Current 2.92M USD +24.4%
Employee-related Liabilities, Current 1.54M USD +47%
Accrued Liabilities, Current 17.2M USD +295%
Liabilities, Current 21.2M USD +191%
Operating Lease, Liability, Noncurrent 4.6M USD +2.04%
Liabilities 25.8M USD +119%
Accumulated Other Comprehensive Income (Loss), Net of Tax -150K USD -1350%
Retained Earnings (Accumulated Deficit) -225M USD -35%
Stockholders' Equity Attributable to Parent 211M USD +112%
Liabilities and Equity 237M USD +112%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD -37.9%
Net Cash Provided by (Used in) Financing Activities 162M USD
Net Cash Provided by (Used in) Investing Activities -68.4M USD -174%
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 63.8M shares +47.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 83.4M USD -1.56%
Deferred Tax Assets, Valuation Allowance 142M USD +8.36%
Deferred Tax Assets, Gross 143M USD +8.29%
Operating Lease, Liability 5.6M USD +10.2%
Depreciation 80K USD +2.56%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.5M USD -79.6%
Lessee, Operating Lease, Liability, to be Paid 7.19M USD +2.71%
Property, Plant and Equipment, Gross 2.24M USD +28.1%
Operating Lease, Liability, Current 992K USD +75.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.47M USD +36%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.54M USD +44.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.6M USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.27M USD +15.1%
Deferred Tax Assets, Operating Loss Carryforwards 45.2M USD +7.09%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.19M USD +6.35%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.17M USD +13.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%